Switching from efavirenz to raltegravir leads to significant improvements in fatty liver disease in people with HIV
Peripheral artery disease more common in people with HIV with lower CD4 counts
PrEP use in US exceeds 100,000 in Gilead pharmacy survey
Incidence of anal cancer has already peaked among HIV-positive gay men; reductions can be achieved with expanded ART coverage and screening
Treatment with DAAs reduces the risk of mortality in the first 18 months after the completion of treatment
Switch from boosted protease inhibitor to dolutegravir reduces lipids in people with HIV at higher risk of heart disease
Boosted darunavir plus lamivudine matches three-drug regimen
European and US regulators approve AbbVie's new combo for all hepatitis C genotypes
Demand for access to NHS PrEP trial looks set to outstrip places
